# Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

> **NCT00986284** · PHASE2 · SUSPENDED · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 102 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00986284
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2009-09
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** Lack of patients and some progressed disease soon after surgery
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00986284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00986284, "Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00986284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*